Benda Subsidiary Benda Ebei Appoints New General Manager.

HUBEI PROVINCE, China -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine([R]), the world's first commercialized gene therapy medicine for the treatment of cancer, announced today the appointment of Mr. Jinghai Xu as General Manager of the Benda Ebei plant effective August 14, 2007.

Mr. Xu, a Chinese licensed pharmacist and senior economist, has over 35 years of experience in the Chinese pharmaceutical industry. Most recently, he served as Associate General Manager of Wuhan Fuxing Biological Pharmaceutical Co., Ltd. Under his leadership, Wuhan Fuxing's revenue grew from $1.3 million in 2004 to $6.6 million in 2006. Prior to working at Wuhan Fuxing, Mr. Xu was the General Manager of Wuhan Hubin Shuang He Pharmaceutical Co., Ltd, the largest intravenous injection supplier in Hubei Province, where he helped grow revenue from $18.5 million in 2000 to $52.9 million in 2004.

Yiqing Wan, Chairman and CEO, stated, "Mr Xu's experience, knowledge of the pharmaceutical industry and proven track record make him a valuable asset to our company. The addition of Mr. Xu, is an example of the efforts Benda is making to further strengthen its core management and increase shareholder value from the inside out."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine([R]), the world's first commercialized gene therapy medicine for the treatment of cancer.

FORWARD-LOOKING STATEMENTS 

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of the Act.